NASDAQ:CAI Caris Life Sciences (CAI) Stock Price, News & Analysis $29.98 -0.94 (-3.04%) Closing price 09/18/2026 04:00 PM EasternExtended Trading$29.94 -0.04 (-0.13%) As of 09/18/2026 07:51 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsInsider TradesNews and TrendsOwnershipSEC FilingsShort Interest About Caris Life Sciences Stock (NASDAQ:CAI) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Caris Life Sciences alerts:Sign Up Key Stats Today's Range$29.69▼$30.9950-Day Range$15.38▼$30.9252-Week Range$14.19▼$34.12Volume14.72 million shsAverage Volume5.05 million shsMarket Capitalization$8.47 billionP/E Ratio83.28Dividend YieldN/APrice Target$26.50Consensus RatingHold Company Overview Caris Life Sciences is a precision medicine and biotechnology company headquartered in Irving, Texas. Founded in 2008, the company combines molecular profiling, artificial intelligence and clinical data to support more informed decisions in cancer diagnosis and treatment. Caris provides comprehensive tumor profiling and other laboratory testing services designed to identify genetic, molecular and immune characteristics of a patient’s cancer. Its offerings are intended to help physicians match patients with targeted therapies, immunotherapies and clinical trials, while also supporting cancer research and drug development. The company serves healthcare providers, biopharmaceutical companies and academic or research institutions. Caris also develops data and software tools that use real-world clinical and molecular information to advance precision oncology. David D. Halbert, who founded Caris, serves as the company’s chairman and chief executive officer.AI Generated. May Contain Errors. Read More Caris Life Sciences Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks64th Percentile Overall ScoreCAI MarketRank™: Caris Life Sciences scored higher than 64% of companies evaluated by MarketBeat, and ranked 281st out of 897 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion2.0 / 5Analyst RatingHold Consensus RatingCaris Life Sciences has received a consensus rating of Hold. The company's average rating score is 2.46, and is based on no strong buy ratings, 7 buy ratings, 5 hold ratings, and 1 sell rating.Downside RiskCaris Life Sciences has a consensus price target of $26.50, representing about 11.6% downside from its current price of $29.98.Amount of Analyst CoverageCaris Life Sciences has only been the subject of 4 research reports in the past 90 days.Read more about Caris Life Sciences' stock forecast and price target. Earnings and Valuation2.5 / 5Proj. Earnings Growth223.08% Earnings GrowthEarnings for Caris Life Sciences are expected to grow by 223.08% in the coming year, from $0.13 to $0.42 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Caris Life Sciences is 83.28, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 44.66.Price to Earnings Ratio vs. SectorThe P/E ratio of Caris Life Sciences is 83.28, which means that it is trading at a less expensive P/E ratio than the Healthcare sector average P/E ratio of about 274.93.Price to Book Value per Share RatioCaris Life Sciences has a P/B Ratio of 14.62. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Short Interest4.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted9.68% of the float of Caris Life Sciences has been sold short.Short Interest Ratio / Days to CoverCaris Life Sciences has a short interest ratio ("days to cover") of 2.45, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Caris Life Sciences has recently decreased by 8.49%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldCaris Life Sciences does not currently pay a dividend.Dividend GrowthCaris Life Sciences does not have a long track record of dividend growth. News and Social Media3.6 / 5News Sentiment0.76 News SentimentCaris Life Sciences has a news sentiment score of 0.76. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.56 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 7 news articles for Caris Life Sciences this week, compared to 4 articles on an average week.Search Interest7 people have searched for CAI on MarketBeat in the last 30 days. This is an increase of 17% compared to the previous 30 days. Company Ownership1.4 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Caris Life Sciences insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $26,966,769.00 in company stock.Percentage Held by Insiders50.00% of the stock of Caris Life Sciences is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsCaris Life Sciences has minimal institutional ownership at this time.Read more about Caris Life Sciences' insider trading history. Receive CAI Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Caris Life Sciences and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. CAI Stock News HeadlinesCaris Life Sciences Stock Jumped 10% Yesterday. Here’s Where Shares Could Go Further in 2026.September 18 at 11:39 PM | finance.yahoo.comCaris Life Sciences (NASDAQ:CAI) Insider Brian Brille Sells 400,000 SharesSeptember 18 at 6:37 AM | insidertrades.comMy top 3 AI picks for the next decadeAlexander Green bought Apple in 1996, recommended Nvidia at a split-adjusted 66 cents in 2004, and picked up Amazon and Netflix under $3 per share in 2005. Now the chief investment strategist at The Oxford Club has identified three AI stocks he believes could be the most profitable investments of the next decade. | The Oxford Club (Ad)Caris Life Sciences: Diagnostics Growth With Room To RunSeptember 17 at 11:00 AM | seekingalpha.comCaris Life Sciences, Inc. (CAI) Soars 9.4%: Is Further Upside Left in the Stock?September 16, 2026 | finance.yahoo.comCaris Life Sciences Launches New National Commercial Featuring Kevin Costner to Raise Awareness of Early Cancer Detection and Caris DetectSeptember 8, 2026 | prnewswire.comCould Caris Life Sciences (CAI) Be 7% Undervalued After Its Lung Cancer Research Update?September 6, 2026 | finance.yahoo.comInsider Selling: Caris Life Sciences (NASDAQ:CAI) President Sells 119,212 SharesSeptember 5, 2026 | insidertrades.comSee More Headlines CAI Stock Analysis - Frequently Asked Questions How have CAI shares performed this year? Caris Life Sciences' stock was trading at $26.98 at the start of the year. Since then, CAI shares have increased by 11.1% and is now trading at $29.98. How were Caris Life Sciences' earnings last quarter? Caris Life Sciences, Inc. (NASDAQ:CAI) posted its earnings results on Thursday, February, 26th. The company reported $0.28 earnings per share for the quarter, topping the consensus estimate of $0.01 by $0.27. The firm's revenue was up 125.4% on a year-over-year basis. Read the conference call transcript. Is Caris Life Sciences doing a stock buyback? Caris Life Sciences' board authorized a share buyback program on Monday, June 8th 2026, which permits the company to repurchase $100,000,000 in shares, according to EventVestor. This means that the company could purchase up to 2.2% of its stock through open market purchases. Stock buyback programs are often an indication that the company's board believes its stock is undervalued. When did Caris Life Sciences IPO? Caris Life Sciences (CAI) raised $459 million in an initial public offering (IPO) on Wednesday, June 18th 2025. The company issued 23,529,412 shares at $19.00-$20.00 per share. Who are Caris Life Sciences' major shareholders? Top institutional investors of Caris Life Sciences include Braidwell LP (2.92%), PointState Capital LP (2.42%), BlackRock Inc. (1.96%) and Canada Pension Plan Investment Board (0.49%). Insiders that own company stock include David Baxley Spetzler, Jon Halbert, Brian J Brille, Luke Thomas Power and Jeff L Vacirca. View institutional ownership trends. How do I buy shares of Caris Life Sciences? Shares of CAI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Company Calendar Last Earnings2/26/2026Today9/19/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Green Zone (1m+) 1-Year History Sep 25 Dec 25 Mar 26 Jun 26 Sep 26 CAI's financial health is in the Green zone, according to TradeSmith. CAI has been in this zone for over one month. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Life Sciences Tools & Services Sub-IndustryLife Sciences Tools & Services Current SymbolNASDAQ:CAI CIK2019410 Webwww.carislifesciences.com Phone(866) 771-8946FaxN/AEmployees1,846Year Founded2008Price Target and Rating Average Price Target for Caris Life Sciences$26.50 High Price Target$33.00 Low Price Target$21.00 Potential Upside/Downside-11.6%Consensus RatingHold Rating Score (0-4)2.46 Research Coverage13 Analysts Profitability EPS (Trailing Twelve Months)$0.36 Trailing P/E Ratio83.28 Forward P/E Ratio230.62 P/E GrowthN/ANet Income-$68.09 million Net Margins10.62% Pretax Margin10.61% Return on Equity18.77% Return on Assets9.34% Debt Debt-to-Equity Ratio0.66 Current Ratio5.53 Quick Ratio4.88 Sales & Book Value Annual Sales$812.03 million Price / Sales10.43 Cash Flow$1.59 per share Price / Cash Flow18.81 Book Value$2.05 per share Price / Book14.62Miscellaneous Outstanding Shares282,600,000Free Float141,298,000Market Cap$8.47 billion OptionableN/A Beta1.10 Social Links 10 Stocks Powering The Next AI Boom The AI boom is creating opportunities across semiconductors, cloud computing, enterprise software, infrastructure, cybersecurity, and automation. Inside this report, you’ll find 10 companies positioned to benefit as artificial intelligence moves from hype to real-world deployment and becomes a core growth driver for corporate America.Get This Free Report This page (NASDAQ:CAI) was last updated on 9/20/2026 by MarketBeat.com Staff. From Our Partners“Elon’s nightmare” could fund your retirementMarc Chaikin, the 60 year Wall Street veteran whose Chaikin Money Flow indicator sits on every Bloomberg termi...Chaikin Analytics | SponsoredYou’ve never seen anything like this beforeFor centuries, families like the Rothschilds, Morgans, and Rockefellers have quietly used one overlooked type ...Porter & Company | SponsoredMy top 3 AI picks for the next decadeAlexander Green bought Apple in 1996, recommended Nvidia at a split-adjusted 66 cents in 2004, and picked up A...The Oxford Club | SponsoredYour $29.97 book is free todayWhy Some Traders Skip Stocks Entirely You don't need a big account to trade options. In fact, options ca...Profits Run | SponsoredNVDA CEO says it’s a "once-in-a-generation opportunity"NVIDIA CEO Jensen Huang calls a little-known AI niche a once-in-a-generation opportunity, and it has nothing t...Monument Traders Alliance | SponsoredTrump goes "all-in" on Grand Canyon energy breakthroughA drilling crew near the Grand Canyon uncovered a clean energy well producing nearly eight times the output of...Behind the Markets | SponsoredA “bloodbath” Is ComingReports suggest some Silicon Valley billionaires are stockpiling gold, guns, and gas masks - or leaving the co...TradeSmith | SponsoredHere’s the stock symbol I’ve promisedWhitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - b...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Caris Life Sciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Caris Life Sciences With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free CAI Stock Alerts